NASDAQ:ONCE - Spark Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $110.70 +0.03 (+0.03 %) (As of 04/25/2019 09:45 AM ET)Previous Close$110.67Today's Range$110.4950 - $110.7752-Week Range$34.53 - $114.20Volume36,410 shsAverage Volume1.06 million shsMarket Capitalization$4.20 billionP/E RatioN/ADividend YieldN/ABeta2.58 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Receive ONCE News and Ratings via Email Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCE Previous Symbol CUSIPN/A CIK1609351 Webwww.sparktx.com Phone888-772-7560Debt Debt-to-Equity Ratio0.09 Current Ratio9.10 Quick Ratio8.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$64.72 million Price / Sales64.93 Cash FlowN/A Price / Cash FlowN/A Book Value$13.15 per share Price / Book8.42Profitability EPS (Most Recent Fiscal Year)($2.11) Net Income$-78,820,000.00 Net Margins-121.78% Return on Equity-14.94% Return on Assets-10.23%Miscellaneous Employees368 Outstanding Shares37,960,000Market Cap$4.20 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions What is Spark Therapeutics' stock symbol? Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE." How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings data on Tuesday, February, 19th. The biotechnology company reported ($1.75) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.89. The biotechnology company had revenue of $13.15 million for the quarter, compared to the consensus estimate of $26.76 million. Spark Therapeutics had a negative return on equity of 14.94% and a negative net margin of 121.78%. The company's revenue was up 47.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.63) earnings per share. View Spark Therapeutics' Earnings History. When is Spark Therapeutics' next earnings date? Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Spark Therapeutics. What price target have analysts set for ONCE? 21 equities research analysts have issued twelve-month price targets for Spark Therapeutics' shares. Their forecasts range from $40.00 to $115.00. On average, they expect Spark Therapeutics' share price to reach $80.3240 in the next twelve months. This suggests that the stock has a possible downside of 27.4%. View Analyst Price Targets for Spark Therapeutics. What is the consensus analysts' recommendation for Spark Therapeutics? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 17 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics. What are Wall Street analysts saying about Spark Therapeutics stock? Here are some recent quotes from research analysts about Spark Therapeutics stock: 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (4/24/2019) 2. William Blair analysts commented, "We see a sound strategic fit with Roche given its recent investment in hemophilia with the launch of Hemlibra (SPK-8011 in hemophilia A, SPK-8016 in hemophilia A patients with inhibitors and royalties from the fidanacogene elaparvovec collaboration with Pfizer), ophthalmology (Luxturna in the United States and royalties from the Luxturna EU launch), and neuroscience (SPK-1001 for CLN2) franchises." (2/26/2019) 3. JPMorgan Chase & Co. analysts commented, "ONCE’s 3Q print encouragingly showed in line Luxturna sales of ~$9M, although a resetting of expectations around the SPK-8011 update at ASH overshadowed launch progress. Given the historical focus on FVIII levels, we aren’t surprised to see disappointment about the news that there will be no biomarker data for the high dose cohort at ASH (there will be clinical outcome data). Indeed, for some time we’ve gotten the sense that at least some investors may wait to see additional SPK-8011 FVIII activity data before re-engaging. That said, today’s update doesn’t fundamentally change the fact that ONCE continues to be a leader in the gene therapy space, with an active early-stage pipeline (2 new programs entering clinic in late- 2018/2019) and an update on SPK-7001 expected by YE18. Maintain Neutral." (11/7/2018) Has Spark Therapeutics been receiving favorable news coverage? News headlines about ONCE stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spark Therapeutics earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term. Who are some of Spark Therapeutics' key competitors? Some companies that are related to Spark Therapeutics include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN) and Crispr Therapeutics (CRSP). What other stocks do shareholders of Spark Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Exelixis (EXEL), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Celgene (CELG), BioMarin Pharmaceutical (BMRN), Amgen (AMGN) and Pfizer (PFE). Who are Spark Therapeutics' key executives? Spark Therapeutics' management team includes the folowing people: Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)Mr. Stephen W. Webster, Chief Financial Officer (Age 58)Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)Mr. Daniel R. Faga, Chief Bus. Officer (Age 39) When did Spark Therapeutics IPO? (ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. Who are Spark Therapeutics' major shareholders? Spark Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Syquant Capital Sas (1.47%), FNY Investment Advisers LLC (0.74%), Havens Advisors LLC (0.07%), Bailard Inc. (0.04%), Harvest Management LLC (0.04%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics. Which institutional investors are selling Spark Therapeutics stock? ONCE stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc.. View Insider Buying and Selling for Spark Therapeutics. Which institutional investors are buying Spark Therapeutics stock? ONCE stock was acquired by a variety of institutional investors in the last quarter, including Syquant Capital Sas, FNY Investment Advisers LLC, Havens Advisors LLC, Harvest Management LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Spark Therapeutics. How do I buy shares of Spark Therapeutics? Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Spark Therapeutics' stock price today? One share of ONCE stock can currently be purchased for approximately $110.70. How big of a company is Spark Therapeutics? Spark Therapeutics has a market capitalization of $4.20 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe. What is Spark Therapeutics' official website? The official website for Spark Therapeutics is http://www.sparktx.com. How can I contact Spark Therapeutics? Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected] MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 462 (Vote Outperform)Underperform Votes: 376 (Vote Underperform)Total Votes: 838MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/25/2019 by MarketBeat.com StaffFeatured Article: What is the QQQ ETF?